Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease-Reference-Cited by-同舟云学术

Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease

Published:2017-03-24 Issue:4 Volume:20 Page:481-488
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Boulos Daniel¹,Ngian Gene-Siew¹,Rajadurai Anton¹,Elford Kathleen¹,Stevens Wendy²,Proudman Susanna³⁴,Owen Claire⁵⁶,Roddy Janet⁷,Nikpour Mandana²⁶,Youssef Peter⁸,Hill Catherine⁴⁹,Sahhar Joanne¹¹⁰

Affiliation:

1. Department of Rheumatology; Monash Health; Melbourne Victoria Australia

2. Department of Rheumatology; St Vincent's Health; Melbourne Victoria Australia

3. Department of Rheumatology; Royal Adelaide Hospital; Adelaide South Australia Australia

4. Discipline of Medicine; University of Adelaide; Adelaide South Australia Australia

5. Department of Rheumatology; Austin Health; Melbourne Victoria Australia

6. Department of Medicine; University of Melbourne; Melbourne Victoria Australia

7. Department of Rheumatology; Royal Perth Hospital; Perth Western Australia Australia

8. Department of Rheumatology; Royal Prince Alfred Hospital; Sydney New South Wales Australia

9. Department of Rheumatology; Queen Elizabeth Hospital; Adelaide South Australia Australia

10. Department of Medicine; Monash University; Melbourne Victoria Australia

Funder

Australian Scleroderma Interest Group

St Vincent's Hospital IT Department and Research Endowment Foundation

Scleroderma Australia

Arthritis Australia

Actelion Australia

GlaxoSmithKline

Pfizer

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1756-185X.13035/fullpdf

Reference26 articles.

1. Cellular and molecular mechanisms of fibrosis;Wynn;J Pathol,2008

2. Evidence-based management of rapidly progressing systemic sclerosis;Khanna;Best Pract Res Clin Rheumatol,2010

3. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR);Kowal-Bielecka;Ann Rheum Dis,2009

4. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis;Clements;Ann Rheum Dis,2007

5. The use of mycophenolate mofetil in transplant recipients;Mele;Immunopharmacology,2000

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of mycophenolate mofetil for the treatment of fibrotic hypersensitivity pneumonitis;The American Journal of the Medical Sciences;2024-07

2. Skeletal Muscle Involvement;Scleroderma;2024

3. Ocular and eyelid involvement in collagen vascular diseases. Part II. Dermatomyositis, scleroderma, and sarcoidosis;Clinics in Dermatology;2023-10

4. Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need;Nature Reviews Rheumatology;2022-03-15

5. Successful treatment of children with juvenile systemic sclerosis using mycophenolate mofetil after methylprednisolone pulse therapy: A 3‐year follow‐up;International Journal of Rheumatic Diseases;2021-12-05